Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Gynaecological Cancers Are Some of Pharma’s Most Important Challenges
Gynaecological cancers remain a major pharma challenge. Explore how disease burden, access, tumour biology, and precision medicine are shaping oncology R&D.
Design and Run Smarter Gynaecological Oncology Clinical Trials
Explore how adaptive design, biomarkers, AI, and smarter recruitment are shaping gynaecological cancer clinical trials and clinical development.
Camizestrant Approval: First ctDNA-Guided Cancer Care
The camizestrant FDA approval is the first for a ctDNA-guided cancer treatment. Find out why the FDA overruled its own advisers and what sponsors must plan next.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Precision Logistics to Speed Up Clinical Trials
Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.